University Hospitals Seidman Cancer Center

Ocular immune-related adverse events with immune checkpoint inhibitors: A retrospective cohort study

Background Immune checkpoint inhibitors (ICIs) are widely used to treat a variety of malignancies. Ocular immune-related adverse events (irAEs) have been increasingly recognized as rare side effects of these medications. Methods We performed a retrospective study of ocular irAEs...

Expanding access to leukemia specialists in the venetoclax era

Acute myeloid leukemia (AML) in older adults was once widely considered incurable. Historical outcomes were particularly poor among patients deemed unfit for intensive chemotherapy, many of whom su...

Genomic and Transcriptomic Landscapes of MEN1-Wild-Type Low-Grade Metastatic Pancreatic NETs Uncover Key Oncogenic Drivers and Targetable Pathways

Sporadic pancreatic neuroendocrine tumors (pNETs) with wild type MEN1 represent a major yet largely ignored subset whose biology and metastatic potential remain poorly understood. Because metastasis can occur despite low histologic grade and modest mutational burden, we hypothesi...

Infliximab for the Treatment of Immune Checkpoint Inhibitor-Associated Acute Kidney Injury

Rishi R Patel, Katherine E Myers, Matthew M Mirsky, Iris Sheng, Arash Rashidi; Infliximab for the Treatment of Immune Checkpoint Inhibitor-Associated Acute

Stereotactic Body Radiotherapy vs Moderately Hypofractionated IMRT for Localized Intermediate-Risk Prostate Cancer

Importance The treatment of prostate cancer with radiotherapy is evolving. How quickly radiotherapy can be delivered, and the relative risks and benefits of such a treatment, is of significant public interest. Objective To determine whether stereotactic body radiotherapy (SBRT) w...